Clinical Trial Detail

NCT ID NCT02717156
Title Recombinant EphB4-HSA Fusion Protein and Pembrolizumab in Treating Patients With Metastatic or Recurrent Urothelial Cancer That Is Refractory to Certain Chemotherapy Drugs
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Southern California
Indications

transitional cell carcinoma

Therapies

Pembrolizumab + sEphB4-HSA

Age Groups: adult

No variant requirements are available.